Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.

Journal Article

The methotrexate analogue 10-ethyl-10-deazaaminopterin (10-EdAM, or edatrexate) has shown antitumor activity in preclinical testing and clinical studies of patients with breast, lung and head and neck carcinomas. A phase II study was conducted in patients with advanced pancreatic adenocarcinoma.Forty patients were enrolled on the clinical trial. Edatrexate was administered intravenously at a dose of 80 mg/m2 weekly for 5 weeks. The treatment course was repeated every 6 weeks.Two partial responses were observed. Both of these patients had partial responses which lasted 2 and 3.5 months. The median survival for all patients was 3.5 months. Serious (grade 3 or 4) toxic effects were primarily mucosal, hematologic, and dermatologic. Two patients experienced severe pulmonary toxic reactions.At the dose and schedule used, edatrexate was poorly tolerated and did not demonstrate significant antitumor activity.

Full Text

Duke Authors

Cited Authors

  • Moore, DF; Pazdur, R; Abbruzzese, JL; Ajani, JA; Dubovsky, DW; Wade, JL; Belt, RJ; Mangold, C; Bready, B; Winn, RJ

Published Date

  • March 1994

Published In

Volume / Issue

  • 5 / 3

Start / End Page

  • 286 - 287

PubMed ID

  • 8186177

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

International Standard Serial Number (ISSN)

  • 0923-7534

Digital Object Identifier (DOI)

  • 10.1093/oxfordjournals.annonc.a058810

Language

  • eng